Inactive Instrument

Kancera AB Share Price Nasdaq Stockholm

Equities

Biotechnology & Medical Research

End-of-day quote Nasdaq Stockholm
- SEK - Intraday chart for Kancera AB
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * - Sales 2025 * 68.9M 6.54M 514M Capitalization 210M 19.95M 1.57B
Net income 2024 * -68M -6.46M -507M Net income 2025 * 53M 5.03M 396M EV / Sales 2024 * -
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 3.05 x
P/E ratio 2024 *
-2.89 x
P/E ratio 2025 *
4.34 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 45.56%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer - 28/02/22
Director of Finance/CFO 75 -
Chief Tech/Sci/R&D Officer - 31/12/12
Members of the board TitleAgeSince
Chairman 63 04/05/10
Director/Board Member 66 31/12/15
Founder 82 27/04/10
More insiders
Kancera AB is a Sweden-based company that develops and sells drug candidates in the field of cancer. The Company's activities are divided into two areas, namely Pharmaceutical Development and Industrial Research and Development (R&D). Pharmaceutical Development area runs such projects, as Project PFKFB3, which aims to develop a drug to combat solid tumors; and Project ROR-1, which aims to develop a drug to combat chronic lymphatic leukemia (CLL). Industrial R&D area consists of the identification of new projects of high potential and of R&D work commissioned by clients. The Company's other activities include development of cancer models and stem cell-based techniques. The Company is active through its subsidiary iNovacia, which carries out analytical development, as well as the identification, validation and further optimization of drug candidates. The Company's operations are conducted at the Karolinska Institutet Science Park in Solna, Sweden.
Calendar
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW